The IMPACCT Rapid Paediatric Program aims to bring together services around the world to gather large amounts of data in a short space of time to improve care of children in palliative care or who are experiencing chronic pain.
Paediatrics
Use the buttons to expand or collapse the section.
Respiratory distress is one of the leading causes to parents presenting with their child to emergency departments, with symptoms being common, recurrent, and distressing. Contemporary research has identified deterioration in respiratory status as being associated with significantly increased morbidity, impacting quality of life, reduced participation and life expectancy.
Physiotherapy is a common first-line strategy requested to relieve increased work of breathing. Physiotherapists experience working with paediatric patients with multiple co-morbidities, including complex neurodisabilities. Choice of management strategy and response to deteriorations need to be individualised to each patient and condition.
By collecting data for this series, you will be helping us to understand current clinical practices of physiotherapy assessment and its impact by identifying key aspects that guide effective intervention selection for respiratory management of acute deteriorations in children and young people with life-limiting conditions.
We want to understand what symptoms medicinal cannabis is being prescribed for in paediatric palliative care.
Medicinal cannabis may be useful for managing treatment-resistant epilepsy, pain and other symptoms that can affect many children in palliative care. Medicinal cannabis may have an adjuvant or complementary role in symptom management but supporting evidence for its use and the most suitable doses is limited.
This series is designed to capture information about what symptoms medicinal cannabis is being prescribed for, whether as a first line treatment or as an adjuvant.
If you’re prescribing medicinal cannabis in palliative care, you can collect data for this series.
Use the buttons to expand or collapse the section.
In this series, we are seeking to establish the broad utility and toxicity of ketamine for children with chronic non-cancer pain in real-life situations.
The series is designed to minimise the workload for any individual site through multi-site collaboration and enable Rapid data collection relatively quickly and easily.
In this study, the data points are at baseline then 48 hours, 72 hours, and 96 hours after baseline, and then three months after the ketamine infusion has ceased. This is reflective of the many conditions that required a longer-term involvement from paediatric chronic pain services and to ensure the opportunity for the majority of children to reach a therapeutic drug level.
If you are prescribing or administering ketamine to children with non-cancer pain, you can help us collect data to improve the available evidence about its effectiveness.
In this series, we are seeking to establish the broad utility and toxicity of ketamine for children with chronic non-cancer pain and cancer pain in real-life situations.
The series is designed to minimise the workload for any individual site through multi-site collaboration and enable Rapid data collection relatively quickly and easily.
In this study, the data points are at baseline then 48 hours, 5 days and 10 days after baseline. This is reflective of the longer-term requirement for analgesia in children with mucositis during their cancer or bone marrow transplant treatment and to ensure the real-life use of ketamine is captured.
Help is collect data to improve the available evidence about the effectiveness of ketamine for children with cancer-related mucositis pain.
We use cookies and similar technologies to provide a better experience
We use scripts (e.g. cookies) that read, store, and write information on your browser. The information we process include your IP address, session details and browsing activity. We use this information to improve our website, personalise your experience and support marketing efforts. Learn more in our Website Privacy Notice.
